OUTCOME OF AZACITIDINE TREATMENT AND INCIDENCE OF FEBRILE EVENTS IN "REAL WORLD" PATIENTS WITH MDS OR LOW-BLAST COUNT AML

被引：0

作者：

Voso, M. T. ^{[1
]}

Niscola, P. ^{[2
]}

Piciocchi, A. ^{[3
]}

Fianchi, L. ^{[4
]}

Maurillo, L. ^{[1
]}

Musto, P. ^{[5
]}

Pagano, L. ^{[4
]}

Mansueto, G. ^{[5
]}

Criscuolo, M. ^{[4
]}

Aloe-Spiriti, M. A. ^{[6
]}

Buccisano, F. ^{[1
]}

Venditti, A. ^{[1
]}

Tendas, A. ^{[2
]}

Piccioni, A. L. ^{[7
]}

Zini, G. ^{[4
]}

Latagliata, R. ^{[8
]}

Filardi, N. ^{[9
]}

Fragasso, R. ^{[10
]}

Fenu, S. ^{[11
]}

Breccia, M. ^{[8
]}

机构：

[1] Univ Roma Tor Vergata, Hematol Biomed & Prevent, Rome, Italy

[2] S Eugenio Hosp, Hematol, Rome, Italy

[3] Univ Roma La Sapienza, Stat Sci, I-00185 Rome, Italy

[4] Univ Cattolica Sacro Cuore, Hematol, Rome, Italy

[5] IRCCS CROB MDS Registry Basilicata, Hematol, Rionero In Vulture, Pz, Italy

[6] S Andrea Hosp, Hematol, Rome, Italy

[7] S Pertini Hosp, Hematol, Rome, Italy

[8] Univ Roma La Sapienza, Hematol, I-00185 Rome, Italy

[9] S Carlo Hosp MDS Registry Basilicata, Hematol, Potenza, Italy

[10] Madonna delle Grazie Hosp MDS Registry Basilicata, Hematol, Matera, Italy

[11] S Giovanni Hosp, Hematol, Rome, Italy

来源：

LEUKEMIA RESEARCH | 2015年 / 39卷

关键词：

D O I：

10.1016/S0145-2126(15)30199-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

198

引用

页码：S99 / S99

页数：1

共 44 条

[1] Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'
Mozessohn, Lee
Cheung, Matthew C.
Mittmann, Nicole
Earle, Craig C.
Liu, Ning
Buckstein, Rena
LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1445 - 1454
[2] Treatment of Low-Blast Count AML using Hypomethylating Agents
De Bellis, Eleonora
Fianchi, Luana
Buccisano, Francesco
Criscuolo, Marianna
Maurillo, Luca
Cicconi, Laura
Brescini, Mattia
Del Principe, Maria Ilaria
Di Veroli, Ambra
Venditti, Adriano
Amadori, Sergio
Arcese, William
Lo-Coco, Francesco
Voso, Maria Teresa
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2017, 9
[3] REAL-WORLD AZACITIDINE USE DOES NOT REPLICATE AZA-001 RESULTS IN HIGHER-RISK MDS/LOW-BLAST COUNT AML: AUDIT OF 1101 PATIENTS IN ONTARIO, CANADA
Mozessohn, L.
Cheung, M.
Fallahpour, S.
Gill, T.
Maloul, A.
Zhang, L.
Lau, O.
Buckstein, R.
LEUKEMIA RESEARCH, 2017, 55 : S41 - S42
[4] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Sekeres, Mikkael A.
Watts, Justin
Radinoff, Atanas
Sangerman, Montserrat Arnan
Cerrano, Marco
Lopez, Patricia Font
Zeidner, Joshua F.
Campelo, Maria Diez
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V.
Ades, Lionel
LEUKEMIA, 2021, 35 (07) : 2119 - 2124
[5] Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
Sebert, Marie
Freiman, Lucie
Chaffaut, Cendrine
Guerci, Agnes
Peterlin, Pierre
Thepot, Sylvain
Beyne-Rauzy, Odile
Park, Sophie
Cluzeau, Thomas
Chermat, Fatiha
Fenaux, Pierre
Preudhomme, Claude
Clappier, Emmanuelle
Chevret, Sylvie
Ades, Lionel
Duployez, Nicolas
Duchmann, Matthieu
LEUKEMIA, 2024, 38 (04) : 918 - 922
[6] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres
Justin Watts
Atanas Radinoff
Montserrat Arnan Sangerman
Marco Cerrano
Patricia Font Lopez
Joshua F. Zeidner
Maria Diez Campelo
Carlos Graux
Jane Liesveld
Dominik Selleslag
Nikolay Tzvetkov
Robert J. Fram
Dan Zhao
Jill Bell
Sharon Friedlander
Douglas V. Faller
Lionel Adès
Leukemia, 2021, 35 : 2119 - 2124
[7] Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
Marie Sébert
Lucie Freiman
Cendrine Chaffaut
Agnès Guerci
Pierre Peterlin
Sylvain Thépot
Odile Beyne-Rauzy
Sophie Park
Thomas Cluzeau
Fatiha Chermat
Pierre Fenaux
Claude Preudhomme
Emmanuelle Clappier
Sylvie Chevret
Lionel Adès
Nicolas Duployez
Matthieu Duchmann
Leukemia, 2024, 38 : 918 - 922
[8] Real-world outcomes in patients with AML and MDS treated with Azacitidine
Prusak, E.
Lawes, M.
Collins, A.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 42 - 42
[9] Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres
Justin Watts
Atanas Radinoff
Montserrat Arnan Sangerman
Marco Cerrano
Patricia Font Lopez
Joshua F. Zeidner
Maria Diez Campelo
Carlos Graux
Jane Liesveld
Dominik Selleslag
Nikolay Tzvetkov
Robert J. Fram
Dan Zhao
Jill Bell
Sharon Friedlander
Douglas V. Faller
Lionel Adès
Leukemia, 2021, 35 : 3637 - 3637
[10] Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study
Voso, Maria Teresa
Leone, Giuseppe
Piciocchi, Alfonso
Fianchi, Luana
Di Bartolomeo, Paolo
Candoni, Anna
Criscuolo, Marianna
Masciulli, Arianna
Cerqui, Elisa
Molteni, Alfredo
Finelli, Carlo
Parma, Matteo
Rivellini, Flavia
Cascavilla, Nicola
Spina, Francesco
Cortelezzi, Agostino
Salvi, Flavia
Montanari, Mauro
Alessandrino, Emilio Paolo
Rambaldi, Alessandro
Sica, Simona
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →